Heman Lapman Chao
Director/Board Member at Helix Immuno-Oncology SA
Profile
Heman Lapman Chao is a Member-Supervisory Board at Helix Immuno-Oncology SA. He previously worked as Director, Chief Executive & Scientific Officer at Helix BioPharma Corp.
from 2017 to 2021.
Prior to that, he was the President of Sensium Technologies, Inc. from 2004 to 2008 and a Manager from 1999 to 2002.
Dr. Chao earned a doctorate degree from Queen's University in 1994.
Heman Lapman Chao active positions
Companies | Position | Start |
---|---|---|
Helix Immuno-Oncology SA
Helix Immuno-Oncology SA Pharmaceuticals: MajorHealth Technology Helix Immuno-Oncology SA engages in the research and development in the area of biotechnology. It develops technology and products with applications in cancer immunotherapy. The company was founded in 2013 and is headquartered in Gliwice, Poland. | Director/Board Member | - |
Former positions of Heman Lapman Chao
Companies | Position | End |
---|---|---|
HELIX BIOPHARMA CORP. | Chief Executive Officer | 2021-08-31 |
Sensium Technologies, Inc.
Sensium Technologies, Inc. Miscellaneous Commercial ServicesCommercial Services Part of Helix BioPharma Corp., Sensium Technologies, Inc. researches and develops drugs and vaccines. Sensium Technologies was acquired by Helix BioPharma Corp. on December 10, 2002 for $3.83 million. | President | 2008-03-31 |
Sensium Technologies, Inc.
Sensium Technologies, Inc. Miscellaneous Commercial ServicesCommercial Services Part of Helix BioPharma Corp., Sensium Technologies, Inc. researches and develops drugs and vaccines. Sensium Technologies was acquired by Helix BioPharma Corp. on December 10, 2002 for $3.83 million. | Corporate Officer/Principal | 2002-05-31 |
Training of Heman Lapman Chao
Queen's University | Doctorate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
Listed companies | 1 |
---|---|
HELIX BIOPHARMA CORP. | Health Technology |
Private companies | 2 |
---|---|
Sensium Technologies, Inc.
Sensium Technologies, Inc. Miscellaneous Commercial ServicesCommercial Services Part of Helix BioPharma Corp., Sensium Technologies, Inc. researches and develops drugs and vaccines. Sensium Technologies was acquired by Helix BioPharma Corp. on December 10, 2002 for $3.83 million. | Commercial Services |
Helix Immuno-Oncology SA
Helix Immuno-Oncology SA Pharmaceuticals: MajorHealth Technology Helix Immuno-Oncology SA engages in the research and development in the area of biotechnology. It develops technology and products with applications in cancer immunotherapy. The company was founded in 2013 and is headquartered in Gliwice, Poland. | Health Technology |
- Stock Market
- Insiders
- Heman Lapman Chao